EUVIMEDOpdag EUVIMED
VergleichsstudieOpen access · CC BY-NC-ND 4.0

Erenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis

María Garcés-Pellejero iD, Marta Torres-Ferrús iD, Rut Mas-de-Les-Valls iD, Edoardo Caronna iD, Alicia Alpuente iD, Eulalia Giné-Ciprés iD, Patricia Pozo-Rosich iD

European Journal of Neurology · 2026-06 · 33 (6)

DOI: 10.1111/ene.70654 ↗

At a glance

Vergleichsstudie in European Journal of Neurology, published online on 2026-06-25. Written by María Garcés-Pellejero and 6 co-authors. Institution: Headache Unit, Neurology Department, Hospital Universitari Vall D'hebron, Barcelona, Spain. Major MEDLINE topics: Botulinum Toxins, Type A, Migraine Disorders, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide Receptor Antagonists. 16 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Instituto de Salud Carlos III, Novartis.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objectives

To compare response (reduction in headache frequency and differences in patient‐reported outcomes) between Erenumab and OnabotulinumtoxinA from two phase‐IV trials after 6 months of treatment. Materials/Methods A prospective cohort study included two parallel cohorts of chronic migraine patients treated with either Erenumab 140 mg/month or OnabotulinumtoxinA 195 U every 3 months. Participants had no additional preventive therapies or comorbid psychiatric or chronic pain conditions. Baseline data collected included demographics, monthly headache (MHD) and migraine days (MMD), impact scales (MIDAS, HIT‐6, MSQ), and anxiety/depression scores (BAI, BDI‐II). Assessments were repeated at 6 months. Baseline characteristics were balanced. Efficacy analysis (measured by reduction in MHD/MMD and impact scales) was conducted using paired t ‐test, and linear regression models compared treatment‐related changes between groups.

Results

A total of 114 patients were analyzed (57 per group), with no significant baseline differences. Both treatments produced significant reductions in headache frequency at 6 months (Erenumab: −7.93 MHD and −5.36 MMD, p < 0.001; OnabotA: −6.00 MHD and −4.31 MMD, p < 0.001), without statistically significant differences between therapies. Significant improvements were observed in HIT‐6 and MSQ scores in both cohorts ( p < 0.05). The Erenumab group showed significant reductions in MIDAS, BDI, and BAI scores ( p < 0.05). Differences between treatments were significant for MIDAS improvements at three and 6 months ( p < 0.05).

Conclusion

Erenumab and OnabotulinumtoxinA are effective preventive treatments for chronic migraine. No significant differences were found in the magnitude of headache reduction at 3 or 6 months when comparing both treatments.

Subjects

MeSH terms (MEDLINE)

Botulinum Toxins, Type AMigraine DisordersAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistsHumansFemaleMaleAdultMiddle AgedChronic DiseaseProspective StudiesTreatment Outcome

Author keywords

CGRPErenumabOnabotAchronic migrainepreventive treatments

Substances

Botulinum Toxins, Type Aonabotulinum toxin AerenumabAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor Antagonists

Authors and institutions

  • Headache Unit, Neurology Department, Hospital Universitari Vall D'hebron, Barcelona, Spain.
  • Headache and Neurological Pain Research Group, Vall D'hebron Research Institute, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.

ORCID profiles: María Garcés-Pellejero, Marta Torres-Ferrús, Rut Mas-de-Les-Valls, Edoardo Caronna, Alicia Alpuente, Eulalia Giné-Ciprés, Patricia Pozo-Rosich

Funding

  • Instituto de Salud Carlos III
  • Novartis

Cite

APA

Garcés-Pellejero, M., Torres-Ferrús, M., Mas-de-Les-Valls, R., Caronna, E., Alpuente, A., Giné-Ciprés, E., & Pozo-Rosich, P. (2026). Erenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis. European Journal of Neurology, 33(6). https://doi.org/10.1111/ene.70654

Vancouver

Garcés-Pellejero M, Torres-Ferrús M, Mas-de-Les-Valls R, Caronna E, Alpuente A, Giné-Ciprés E, et al. Erenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis. European Journal of Neurology. 2026;33(6). doi:10.1111/ene.70654

BibTeX
@article{GarcsPellejero2026,
  author = {Garcés-Pellejero, María and Torres-Ferrús, Marta and Mas-de-Les-Valls, Rut and Caronna, Edoardo and Alpuente, Alicia and Giné-Ciprés, Eulalia and Pozo-Rosich, Patricia},
  title = {Erenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {6},
  doi = {10.1111/ene.70654}
}
Start for free →